Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if it is safe and feasible to apply PRT-201 to the adventitia of arteries following successful angioplasty (PTA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

NCT02953496

Peripheral Artery Disease

WITHDRAWN PHASE1

Clinical Study of Stent Versus Direct Atherectomy to Treat Arteriosclerosis Occlusive Disease of Lower Extremity

NCT02840786

Atherosclerosis Ischemia

COMPLETED NA

Comparison of a Lithotripsy vs Standard Preparation Followed by Stenting With Supera Stent in Femoropopliteal Lesions

NCT06112171

Peripheral Arterial Disease

RECRUITING NA

Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND)

NCT00906022

Patients With Symptomatic Critical Limb Ischemia Severe Intermittent Claudication

COMPLETED PHASE4

Clinical Study of Focal Implant Used for Lower Extremity Post-angioplasty Dissection

NCT05562076

Peripheral Artery Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRT-201

0.03, 1, or 3 mg single adventitial administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age of at least 18 years
2. Clinical diagnosis of PAD, secondary to atherosclerosis affecting a lower limb
3. Rutherford classification 2-4 (moderate claudication to ischemic rest pain)
4. ABI \<0.90 at rest or with exercise, or a toe-brachial index \<0.70, or radiographic evidence of PAD that correlates with clinical symptoms
5. De novo lesion, not previously treated by angioplasty or atherectomy
6. Greater than 70% stenosis of the SFA or PA, target lesion length of 10 cm or less, and at least one patent runoff vessel. Short segment occlusions (\<10 cm) are acceptable
7. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 1 week following study drug administration. Acceptable methods of birth control include abstinence, barrier methods with spermicide, implants, injectables, oral contraceptives, intra-uterine device, or a vasectomized partner
8. Ability to understand and comply with the requirements of the entire study and communicate with the study team
9. Ability to provide written informed consent using a document that has been approved by the required institutional review board

Exclusion Criteria

1. Previous treatment with PRT-201
2. Patients in whom arterial insufficiency in the lower extremity is the result of an immunologic or inflammatory non-atherosclerotic disorder (e.g. Buerger's disease, vasculitis)
3. Current severe critical limb ischemia defined as ulceration or gangrene
4. Planned atherectomy of the arteries of the index leg
5. Prior or planned stenting of the target lesion
6. Prior bypass surgery to the target SFA or PA
7. Severe concentric medial calcification of the target lesion thought to interfere with drug delivery to the adventitia that is defined subjectively by the Investigator based on fluoroscopic appearance.
8. History of metastatic cancer
9. Presence of aortic or peripheral artery aneurysm
10. Platelet count \<130K, hematocrit \<30%, bilirubin or ALT \>3.0 times the upper limit of normal
11. Pregnancy, lactation or plans to become pregnant during the course of the study
12. Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study
13. Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within 90 days prior to signing informed consent
14. Known allergy to contrast media

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No